Exploratory evaluation of blood markers of liver disease in heart failure

Date Added
October 27th, 2026
PRO Number
Pro00152518
Researcher
Karim Besir

List of Studies

Keywords
Heart, Liver
Summary

This research study is being conducted to better understand the relationship between heart disease and liver disease. We are enrolling adults with heart failure and fatty liver disease who are already scheduled to undergo a cardiac catheterization as part of their routine medical care. Participants will have additional blood collected during their cardiac catheterization using the lines or catheters placed for the procedure. Approximately 50 mL of blood will be collected for research to study proteins that may help us better understand how the heart and liver affect one another. The research team will also collect relevant health information from participants' medical records. Participation will not require an additional cardiac catheterization or additional research visits.

Institution
MUSC
Recruitment Contact
Bridgette Blankenship
843-876-8439
blanke@musc.edu

A Single-Site, Mixed-Methods Study Identifying Barriers and Facilitators to Genetic Counseling Referral among Patients with Hypermobile Ehlers-Danlos Syndrome

Date Added
October 5th, 2026
PRO Number
Pro00151523
Researcher
Alyssa Hill

List of Studies

Keywords
Arthritis, Autoimmune disease, Bladder, Bone, Bowel, Cardiovascular, Central Nervous System, Children's Health, Digestive System, Ethnicity and Disease, Fibromyalgia, Genetics, Heart, Immune System, Inflammation, Inflammatory Bowel Disease, Joint, Lupus, Minorities, Movement Disorders, Muscle, Nerve, Nervous System, Pain, Pediatrics, Physical Therapy, Rare Diseases, Rheumatoid, Stomach, Stress Disorders
Summary

This research study aims to better understand patient experiences with accessing genetic counseling services for hypermobile Ehlers-Danlos syndrome (hEDS). The study will include a review of MUSC medical records to better understand referral patterns to genetic counseling services among patients with hEDS. Patients with hEDS will also be asked to complete a survey about their experiences with accessing genetic counseling services. Healthcare providers will be asked to complete a separate survey about their experiences referring patients with hEDS to genetic counseling services and potential factors that may influence the referral process. The surveys will take approximately 10-15 minutes to complete.

There are minimal risks to participants but may include possible loss of confidentiality or discomfort when answering questions related to healthcare experiences. There is no direct benefit to participants, but the information provided may help improve access to genetic counseling services for future patients with hEDS. Participation in the surveys is completely voluntary.

Institution
MUSC
Recruitment Contact
Alyssa Hill
3159552243
hillsu@musc.edu

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction

Date Added
September 8th, 2026
PRO Number
Pro00151613
Researcher
Daniel Silverman

List of Studies

Keywords
Heart
Summary

This Phase 3 research study is evaluating whether an oral form of the investigational medication levosimendan can improve exercise ability, symptoms, and overall health in people with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). Investigational means that this drug is not approved for general use but is still being developed in clinical trials like this one for safety and effectiveness. Participants will be randomly assigned to receive either levosimendan or a placebo during the first stage of the study, and neither they nor the study team will know which treatment they receive until that stage is complete. Researchers will monitor participants through clinic visits, phone calls, physical exams, heart imaging, blood tests, questionnaires, and walking tests to evaluate how well the medication works and how safe it is. After completing the first stage, participants may choose to join an optional second stage in which everyone receives levosimendan. This study will last approximately 2 and a half years over approximately 20 in office visits. The information collected from this study may help determine whether oral levosimendan is a safe and effective treatment option for people living with PH-HFpEF.

Institution
MUSC
Recruitment Contact
Madison Johnson
(843) 792-4615
johme@musc.edu

A Phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients, from birth to 18 years of age, with left ventricular systolic dysfunction (LVSD)

Date Added
August 28th, 2026
PRO Number
Pro00149200
Researcher
Katerina Boucek

List of Studies

Keywords
Heart, Pediatrics
Summary

The FIORELLO study is for pediatric patients who 1) Have heart failure and left ventricular systolic dysfunction associated with dilated cardiomyopathy or congenital heart disease and 2) Have successfully completed the FIORE trial. Study participants will receive the study drug finerenone, which has not yet been FDA approved for this specific pediatric population. The study will last 9 months and the objective is to show that finerenone in addition to standard of care is safe when given long-term to pediatric patients with left ventricular systolic dysfunction.

Institution
MUSC
Recruitment Contact
Susannah Wakefield
8437928317
wakefies@musc.edu

PALMS-HF: Post-Acute Longitudinal Monitoring System for Heart Failure in Rural Populations

Date Added
August 26th, 2026
PRO Number
Pro00151094
Researcher
Michele Esposito

List of Studies

Keywords
Heart
Summary

This is a pilot study that will be performed to assess whether a series of once weekly in-home visits over a month (total of 4 visits) after discharge from a hospital with a heart failure diagnosis can help reduce re-hospitalization rates. To accomplish this, subjects will perform a once weekly telehealth visit with a heart failure provider and the following will be completed: symptom questionnaires, blood work, and a video of the neck veins to document physical exam once weekly during the study period. The videos and labs will be sent to the remote care team, who can use this data to manage the subject's medications. The study team will collect information regarding the study participant's frequency of hospital readmissions following enrollment.

Institution
MUSC
Recruitment Contact
Shaquanda Goodwine
843-876-5783
shr37@musc.edu

A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age with heart failure (HF) and left ventricular systolic dysfunction (LVSD)

Date Added
July 22nd, 2026
PRO Number
Pro00148694
Researcher
Katerina Boucek

List of Studies

Keywords
Heart, Pediatrics
Summary

This is a 3 month study for pediatric patients between the ages of 6 months and 18 years that have a current diagnosis of heart failure. This study will compare the use of the medication finerenone to placebo. During the study, participants will continue to receive their standard of care therapy according to pediatric heart failure guidelines. At the end of the 3 month study period, participants will have the option to enroll in a 9 month open label extension.

Institution
MUSC
Recruitment Contact
Susannah Wakefield
843-792-8317
wakefies@musc.edu

VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients with Symptomatic Severe Tricuspid Valve Regurgitation

Date Added
July 14th, 2026
PRO Number
Pro00151286
Researcher
Nicholas Amoroso

List of Studies

Keywords
Heart, Surgery
Summary

This study is enrolling patients with severe tricuspid regurgitation. Tricuspid regurgitation happens when your heart's tricuspid valve does not close tightly. The study will look at the safety and function of the investigational VDyne Transcatheter Tricuspid Replacement System (VDyne System). The VDyne System (Study Device) is experimental, which means it is not approved by the Food and Drug Administration (FDA), or any other relevant regulatory authority for commercial use. The VDyne System consists of an artificial heart valve and tools to place the valve into your heart. The VDyne Valve is designed to replace your tricuspid heart valve without open-heart surgery.

This study is randomized, meaning you will be assigned by chance to receive either the Study Device or the EVOQUE system, which is commercially approved by the FDA. The EVOQUE System is approved for use in the European Union (EU) (CE Mark) and the US (FDA).

Participation in this study will last about 5 years and include about 11 visits. Study related procedures included in these visits are physical exams, questionnaires, walking and moving from sitting to standing tests, blood tests, electrical measure of your heart's performance, ultrasound imaging of your heart, insertion of a thin tube to measure pressures through a blood vessel and monitor blood flow through your heart, and X-rays.

There are risks associated with the study such as: bleeding, injury to the system that controls your heartbeat, movement of the VDyne Valve from its implanted location, irritation of your esophagus, pain, inflammation, and skin/tissue injury. There are also risks related to study procedures such as other risks related with putting you to sleep for the procedure (general anesthesia) or other study related testing risks and the loss of confidentiality. Not all risks are known at known at this time. There may be benefit to you, although this cannot be guaranteed, but the information gained from you being in this study may benefit others with this condition in the future

Institution
MUSC
Recruitment Contact
Natalie Forrester
843-876-5037
drain@musc.edu

Prospective RandomizEd Evaluation and Management of Premature Therosclerosis

Date Added
July 10th, 2026
PRO Number
Pro00151795
Researcher
Sheldon Litwin

List of Studies

Keywords
Cholesterol, Heart
Summary

The PRE-EMPT study is designed to identify people who may have early signs of heart disease even though they are considered to be at low risk for heart problems. Participants will undergo specialized heart scans to look for plaque buildup in the arteries that supply blood to the heart. Individuals found to have early plaque may be invited to participate in a treatment phase of the study. In this phase, participants will receive either study medications (rosuvastatin and/or colchicine) or placebo tablets and will also receive support for healthy lifestyle behaviors through a digital health platform. Patients will be randomized to one for four treatment groups. Researchers will follow participants for approximately two years to determine whether these treatments and lifestyle interventions can slow or reduce plaque buildup in the heart arteries. Information gained from this study may help improve strategies for detecting and treating early heart disease in the future.

Institution
MUSC
Recruitment Contact
Melissa Amitrano
8438765009
amitrano@musc.edu

Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).

Date Added
June 9th, 2026
PRO Number
Pro00150347
Researcher
Daniel Silverman

List of Studies

Keywords
Diabetes, Drug Studies, Heart, Kidney, Obesity
Summary

Individuals with obesity and a history of heart failure (condition where heart does not effectively pump) with a preserved or mildly reduced ejection fraction (measure of the heart's pumping ability) will be eligible for participation. Study participants will have a 50:50 chance to be randomly assigned to either the treatment (NNC0487-0111) or control (placebo) group. NNC0487-011 and placebo will be delivered in an injectable pen device for a subcutaneous, once weekly injection. Placebo means there is no active study treatment) Study participation will last approximately three years and begin with a screening period to ensure correct patient selection. After the screening period, research clinic visits will occur every 4 weeks initially and then every 12 weeks. Some visits may be completed virtually through telehealth or by phone. Study procedures include but are not limited to: blood draws, questionnaires, self injection of study medication, medical history review, vital signs, and electrocardiogram (test that records the heart's electrical activity) The study's primary objective is to demonstrate that study drug vs. once weekly placebo, with standard of care, reduces the risk of a composite heart failure outcome consisting of cardiovascular death, heart failure hospitalization, or urgent heart failure visit in patients with heart failure with a preserved or mildly reduced ejection fraction and obesity.

Institution
MUSC
Recruitment Contact
Elhaam Borhanian
843-792-5873
borhania@musc.edu

Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure

Date Added
June 9th, 2026
PRO Number
Pro00150995
Researcher
Sheldon Litwin

List of Studies

Keywords
Heart
Summary

This study is enrolling subjects with heart failure and a preserved fraction meaning the heart is too stiff to fill properly to meet the body's needs. This study is researching an investigational device (study device) called the Alleviant ALV1 System. Investigational means it has not been approved for commercial use by the Food and Drug Administration. (FDA) This study will test the safety and effectiveness of the Alleviant ALV1 System. The Alleviant ALV1 System is intended to create a shunt (an opening) in the heart to allow for proper blood flow through the heart which may improve your symptoms. No device is left in your heart it is just used to create the shunt. This is a randomized study which means subjects are assigned by chance to either have the study device create this shunt or not have the study device create the shunt. Randomization is 50/50 meaning there is a 50% chance to have the study device create a shunt and a 50% chance the study device will not be used. Using the study device to create the shunt is performed during a right heart catheterization (RHC) so all subjects will undergo the RHC but only 50% will have the shunt. Neither the subjects nor the study doctor will know which group subjects are randomized to but other study staff will know in the event this information is needed. All subjects will stay overnight in the hospital after the procedure. Other study related procedures include echocardiograms - ultrasound test of the heart, electrocardiograms (ECG) - a tracing of the heart's electrical activity, blood work, questionnaires, 6 minute hall walk test, and assessments of heart failure status. Risks include risks related to the study device including blood vessel damage from placing the device in the vein to get to the heart, risks from the right heart catheterization such as bleeding or bruising, abnormal heart beats, and risks related to study related procedures. There may be risks that are not known at this time. Participation in this study is expected to last about 60 months and include approximately 15 in person visits and 3 telephone calls.

Institution
MUSC
Recruitment Contact
Shaquanda Goodwine
8438765783
shr37@musc.edu



-- OR --